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ABSTRACT
Arthrogryposis is a clinical description of a phenotype caused by fetal 
immobility. More than 150 conditions presenting with congenital 
arthrogryposis are known. Prenatally lethal cases of arthrogryposis present a 
diagnostic challenge although they are more frequently encountered due to 
improved ultrasound methods.  Post-mortem diagnostics is often hampered 
by fetal maseration. Therefore, accurate diagnosis is at times only descriptive 
and prognosis is not always possible to predict. The incidence of anterior horn 
cell disorders associated with arthrogryposis and early fetal demise is poorly 
known. Thus, more knowledge about the genetics and epidemiology of these 
disorders is needed. Importantly, identification of the defective pathways in 
these disorders would most probably expose critical elements in the normal 
development of human motoneurons. 
The Finnish Disease Heritage includes two lethal arthrogryposes. The 
pathogenetic mechanism of these diseases is still unknown. This thesis sheds 
light on the molecular mechanisms active during the pathogenesis of Lethal 
Congenital Contracture Syndrome. LCCS leads to death of the affected 
fetuses before the 32nd gestational week. The hallmark of the syndrome is 
degeneration of the anterior horn of the spinal cord. We localized the 
defective gene to chromosome 9q34.1 and provided a scaffold to sequence 
the genomic region. We then continued by the analysis of the positional 
candidate genes in the critical DNA-region, but until now the LCCS gene and 
the corresponding mutation remains unknown. 
To obtain further clues of the character of the LCCS gene and involved 
pathways, we performed DNA microarray experiments on LCCS spinal cords 
to unravel the molecular pathways that are deranged during the disease 
process. We observed changes in central developmental themes, including 
Sonic Hedgehog in addition to an indication of oligodendrocyte dysfunction. 
To address the implicated oligodendrocyte dysfunction further, neural 
precursor cells were harvested from post-mortem LCCS CNS and cultured in 
vitro.
Neural precursor cells from both LCCS patients and age-matched controls 
were succesfully enriched in culture. The LCCS neural precursor cells 
appeared denser and assessment of proliferation indicated increased mitotic 
6activity. Transcript analysis provided a molecular explanation to the observed 
phenomenon. The neural precursor cells of LCCS patients seemed to respond 
normally to differentiating stimuli of  morphogens suggesting their normal 
initial development and implying problems at later stages of differentiation of 
the cells of spinal cord. However, distinct differences were observed in the 
transcript profiles of LCCS patients when compared to controls. Aberrant 
apoptosis during initial differentiation was not found in LCCS neural 
precursor cells. 
LCCS accounts for the majority of prenatally lethal arthrogryposes in Finland. 
To determine the true number of LCCS cases, we estimated the birth 
prevalence of LCCS to 1: 25300 births through a register based study during 
1987-2002.
The intricate developmental network of the spinal cord is subjective to 
disturbances at multiple occasions. This thesis shows that neural precursor 
cells can propagate and differentiate in culture, and thus, most developmental 
checkpoints are passed normally at least in culture in LCCS patients. Most 
probably, the disease mechanism is active at post-mitotic stages of the spinal 
cord cells. 
Keywords: LCCS, Arthrogryposis, Development, Motoneurons, 
Oligodendrocytes, Stem cells, Epidemiology 
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1. INTRODUCTION 
Development is an intricate process during which cells pass different 
stages and interact to establish an organism. Disturbances in development 
lead to congenital diseases. Lethal arthrogryposis results from fetal 
immobility and is manifested by distinct features consisting mainly of joint 
contractures and facial anomalies. It can be caused by intrinsic or extrinsic 
reasons. Lethal Congenital Contracture Syndrome (LCCS) is a lethal 
arthrogryposis part of the Finnish Disease Heritage. LCCS leads invariably 
to fetal death before the 32nd gestational week. The fetuses show the Fetal 
Akinesia Deformation Sequence (FADS) with severly atrophic muscles. 
The hallmark lies in the developmental defect of the spinal cord, where 
degeneration of the anterior horn and descending tracts are observed. The 
molecular background of LCCS has not been characterized. Here we 
present investigations on the genetic background of Lethal Congenital 
Contracture Syndrome, a human disorder with an unknown defect. The 
characterization of the involved molecular pathways should result in the 
identification of a critical steps in the development of the spinal cord.  
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2. S U R V E Y  O F  T H E  L I T E R A T U R E  
DEVELOPMENT OF THE HUMAN EMBRYO 
The early stages 
Development relies on the transient stages of cells. An embryo is being 
built from a single cell, that through continuous symmetric and 
asymmetric cell division slowly gives rise to a remarkable organism 
(Gilbert, 1997). The embryo absorbs information from both its genes and 
the surrounding environment during development, establishing symbiosis 
of genotype and phenotype. Fertilization is initiated by the combination of 
the genetic material of the sperm and egg giving rise to a new organism, 
the zygote. In preparation for fertilization, the germ cells undergo meiosis 
to reduce the number of chromosomes to haploid. The germ cells also 
differentiate for proper function. Fertilization occurs in the uterine tube, 
from where the zygote undergoes a series of rapid mitotic divisions 
generating a blastula while journing to the site of implantation in the 
uterus (Adams et al., 1956; Egarter, 1990). Cleavage is asynchronous after 
the two-cell stage with one of the two blastomeres dividing to form a three 
cell embryo. Subsequently, embryogenesis is established, during which the 
developing embryo is growing and preparing for the life after birth. As the 
blastula reaches the 16-cell stage it is called a morula deriving from the 
latin word for mulberry. This period is followed by a decline of the mitotic 
rate and a displacement of the cells termed gastrulation starting during the 
second week. Gastrulation gives rise to the three germ layers, ectoderm, 
mesoderm and endoderm, situated from the outside progressing inside, 
respectively (Tam and Beddington, 1987). The embryo develops 
cephalocaudally meaning that gastrulation continues in caudal segments 
while cranial structures start to differentiate. 
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Formation of the germ layers is followed by a period relying on active 
cellular interactions, where tissues and organs are formed. The initiation of 
gastrulation is a highly sensitive period for extrinsic insult, but the sensitive 
period does continue during the whole period of organogenesis. After 
formation of tissues and organs, the embryo is mostly occupied with 
growth and maturation. These two features will continue well beyond birth 
and are subjective to surrounding signals. 
Development of the central nervous system 
The nervous system is one of the earliest organ systems to differentiate 
from the blastula in the embryo. The central nervous system (CNS) 
develops from the ectoderm, giving rise to the various cell types of the 
mature nervous system. The CNS appears during the 3rd week as the 
neural plate, a thickened part of ectoderm located in front of the primitive 
pit. The lateral edges of the primitive pit elevate, approach and eventually 
fuse between 18 and 26 days of gestation to form the neural tube (Muller 
and O'Rahilly, 1987). By the 7th week, the cephalic portion of the neural 
tube has processed dilations from which the brain is developed. The 
caudal neural tube increases in size parallel to the growth of the embryo 
and differentiates to form the spinal cord (Cowan, 1979; Herschkowitz, 
1988). The peripheral nervous system (PNS) develops from the neural 
crest cells, which have differentiated from the developing neural tube and 
migrated to specific regions. Migration is paramount as well in establishing 
the CNS and during the first 20 weeks, when neurons and glial cells 
migrate from the germinal sites in the subventricular zones and central 
canal of the spinal cord to their destinations. The ventral midline portion 
of the neural tube is called the floor plate and it is central in orchestrating 
the development of the spinal cord. The floor plate cells of the notochord 
secretes paracrine factors that pattern the spinal cord to distinct domains. 
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These domains further continue to specialize into distinct cell types. Sonic 
Hedgehog (Shh) is central in the patterning of the early spinal cord 
(Stamataki et al., 2005). The Shh pathway is relayed by the GLI family of 
transcription factors (Jessell, 2000). Mutations of Shh in human have been 
noted as causative of holoprosencephaly (Roessler et al., 1996) and also to 
impair neural patterning activity (Schell-Apacik et al., 2003). The actions of 
Shh regulates the expression of a distinct set of homeodomain and basic-
helix-loop-helix transcription factors which fall into two categories: class I 
proteins, that are repressed by Shh and class II proteins that are activated 
by Shh (Briscoe et al., 2000). These transcription factors promote the 
development of the pMN domain in the anterior horn of the spinal cord 
(see figure 1 for specification of the pMN domain by the transcription 
factors Pax6, Nkx2.2, Olig2 and Irx3), from which both motoneurons and 
oligodendrocytes develop (Jessell, 2000; Briscoe and Ericson, 2001). Some 
controversy has been raised on the common origin of motoneurons and 
oligodendrocytes and it remains unclear whether or not these two cell 
types share a common progenitor cell (Rowitch et al., 2002; Noble et al., 
2004). The formation of both cell types is dependent on the action of 
Olig2, a bHLH transcription factor first identified in oligodendrocyte 
development (Zhou et al., 2000; Takebayashi et al., 2002). Olig2 functions 
in concert with other transcription factors. When Olig2 is coexpressed 
with Neurogenin2, motoneurons are developed from the pMN domain 
(Takebayashi et al., 2002). As development proceeds a little further, the 
expression of Neurogenin2 is downregulated and Olig2 is coexpressed 
with Nkx2.2, oligodendrocytes are generated from the same pMN domain 
(Zhou et al., 2001).  
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In addition to hedgehog-related signaling, other components play specific 
roles during the development of the spinal cord. Wnt signaling is essential 
for the maintenance of neural progenitor cell proliferation, for controlling 
the size of the progenitor population, and to influence the decision of 
progenitor cells to differentiate or proliferate (Zechner et al., 2003). 
Further, Wnt signaling has been identified as dorsal factors that directly 
inhibit oligodendrocyte development. The addition of a Wnt antagonist 
rmFz-8/Fc, increases the number of immature oligodendrocytes in vitro 
spinal cord explants, demonstrating that endogenous Wnt signaling 
controls oligodendrocyte development (Shimizu et al., 2005). FGF 
signaling is involved in motoneuron development by controlling Hox 
expression (Dasen et al., 2003). 
Figure 1. The formation of the motoneuron precursor domain and the postmitotic 
cells determined by the expression of specific transcription factors. P represents for 
precursor domains, V for postmitotic cells. 
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The identity of motoneurons 
As motoneurons exit the cell cycle, they acquire columnar subtypes 
revealed by the position of the cell soma in the spinal cord and by the 
pattern of peripheral projections (Landmesser, 1978; Tosney et al., 1995). 
There are five columnar groups of motoneurons; two are found in the 
median motor column supplying to axial muscles, one set is the pre-
ganglionic autonomic motoneurons and the remaining two groups are 
found within the lateral motor column at limb levels of the spinal cord 
(Landmesser, 1978; Prasad and Hollyday, 1991). The medial lateral motor 
column motoneurons supply ventrally derived limb muscles whereas 
lateral motor column motoneurons project axons to dorsally derived limb 
muscles (Landmesser, 1978; Tosney et al., 1995). The columnar identity of 
motoneurons can be distinguished by the expression profile of LIM 
homeodomain transcription factors. Islet-1 expression is required for the 
generation of all spinal motoneurons (Pfaff et al., 1996), Lhx 3 and Lhx4 
denote medial MMC identity (Sharma et al., 1998). The expression of the 
homeodomain protein MNR2 persists in motoneurons of the medial 
MMC, whereas HB9 is expressed more widely in somatic motoneurons. 
The downregulation of MNR2 and HB9 expression is needed for the 
generation of preganglionic autonomic motoneurons (William et al., 2003).  
Glial cell origin 
Glial cell maturation partly parallels and overlaps neuronal differentiation. 
The precursor cells maturate in the specific domains and aggregate with 
neurons to form the specific brain regions. The number of glial cells is 
regulated such, that the proportion of neurons to glia is maintained at 1:10 
(Sommer and Rao, 2002). The two main classes of glial cells, the 
oligodendrocytes and astrocytes, serve different functions in the nervous 
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system. Astrocytes are more versatile and they can be distinguished by the 
expression of Glial Fibrillary Acidic Protein (GFAP) (Eng et al., 1971; 
Bignami et al., 1972). Other glial cell types also exist including radial glia, 
pituary glia and olfactory ensheathing cells.  
As the precursor cells in the specific domains differentiate, they generate 
more restricted precursors that undergo progressive maturation. 
According to this model at least three types of restricted precursors exist: 
the neuronal precursors, the glial precursors and the neural crest 
precursors (Rao, 1999). In reality, additional precursors are likely to exist 
as several other precursors have also been identified (Rowitch et al., 2002). 
These include oligodendrocyte and type-2 astrocyte precursors (Raff et al., 
1983), glial restricted precursors (Rao et al., 1998), polydendrocytes 
(Nishiyama et al., 1997), motoneuron-oligodendrocyte precursors (Lu et 
al., 2002; Sun et al., 2003), astrocyte precursor cells (Liu and Rao, 2004), 
and white matter precursors (Roy et al., 1999).  How these precursors 
relate to others remains unclear. Multiple developmental pathways may 
exist, however, revision to current models is needed. 
Programmed Cell Death during development 
As motoneurons mature, they start sending axons out to the periphery 
during the 5th week (Sariola et al., 2003). When they reach their target 
muscles, a period of programmed cell death (PCD) ensues, during which 
superfluous or nonfunctional motoneurons are eliminated. Approximately 
50% of the developed motoneurons undergo PCD. Most cell types of the 
CNS encounter a similar destiny and it has been shown that PCD is an 
essential component of development (Oppenheim, 1991; Sendtner et al., 
2000; Sommer and Rao, 2002). Much of developmental PCD is executed 
via apoptosis (Vaux and Korsmeyer, 1999). Central components in the 
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apoptosis cascade are the caspase family of proteases (Troy and Salvesen, 
2002). The regulation of caspases is complex and is achieved by 
interactions of pro- and antiapoptotic regulators (Danial and Korsmeyer, 
2004). Shh has been implicated as a regulator of apoptosis, where too 
much or too little Shh expression results in an increase of apoptosis 
(Oppenheim et al., 1999; Charrier et al., 2001; Paganelli et al., 2001). 
Survival of motoneurons through the period of PCD requires activity in 
the form of both afferent input and efferent response, trophic factors and 
cell interaction between the neurons and adjacent Schwann cells 
(Hamburger, 1934; Levi-Montalcini and Levi, 1942; Riethmacher et al., 
1997). In addition, motoneuron PCD can be experimentally reduced by 
various factors including steroids (Nakamizo et al., 2000), growth factors 
(Ang et al., 1992), neurotrophic factors (Zhao et al., 2004) and 
neuromuscular blocking agents (Oppenheim, 1991). 
Stem Cells 
As cells differentiate, they reach a state of full function that is considered 
irreversible. The next step of differentiation is apoptosis, which eliminates 
the cell. These cells, if needed, are compensated for by less differentiated 
cells that are capable of self-renewal and retain the potential to 
differentiate depending on their specific environments. These cells are 
called stem cells. In the early embryo, the stem cells are uncommitted and 
before the blastocyst stage they are totipotent. The potency of cells 
describes the amount of options the cell has to differentiate. As 
development proceeds, the fate of the cells becomes somewhat more 
restricted (see figure 2 for schematics of cell potency as a function of 
time). According to current knowledge, adult stem cells have a pluripotent 
capacity and their fate is dependent on regional and developmental 
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contexts. The definition of stem cells is based on their capacity to self 
renew and differentiate under the appropriate stimuli. It has however been 
suggested that stemness is a state in the life cycle of the cell (Zipori, 2004). 
What actually determines the outcome is the environment in which the cell 
resides. Stem cells are dependent on their niche, which keeps them 
undifferentiated (Doetsch, 2003). Creating of these niches for stem cells in 
vitro is a challenge to be solved. 
Each tissue is constructed from tissue specific stem cells which respond to 
activating signals when needed. As differentiation proceeds, the number of 
stem cells is reduced. In regions of ongoing development, small numbers 
of stem cells are still encountered in the adult. Adult tissues also contain 
cells that display pluripotent capacity in vitro cultures. Multipotential adult 
progenitor cells capable of differentiating into mesodermal derivates, 
ectodermal cells and to endodermal products have been found from bone 
marrow (Jiang et al., 2002). Further, skin progenitor cells have been shown 
to differentiate into mesodermal derivatives and neuroectoderm (Toma et 
al., 2001). Thus, pluripotent stem cells prevail in the adult organism. 
Embryonic stem cells can in contrast to adult stem cells be amplified for 
long periods in vitro. An embryonic stem cell stems from the blastocyst 
and hence can generate all functional adult cell types. Much anticipation 
Figure 2. Potency of progenitor cells as a function of developmental stage. 
Straigth line indicates ES cells, curved line adult stem cells. 
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has therefore been laid on tissue replacement therapies for various 
conditions, including myocardial disorders, diabetes and neurological 
disorders (Mayhall et al., 2004; Davani et al., 2005).  
The dark side of stem cells is their close resemblance to cancer cells. 
Cancer cells are defined by their properties to reproduce beyond normal 
restraints and to invade regions of other cells. In these terms, stem cells 
bear close resemblance to cancer cells, and indeed several solid cancer 
forms have been found to originate from stem cells (Reya et al., 2001; 
Pardal et al., 2003; Singh et al., 2004). Thus, for therapeutics to be safe, we 
need to understand how stem cells are controlled before interventions 
become daily practice. To turn the coin around, by understanding stem cell 
characteristics, we gain much in the knowledge of cancer cells. 
Neural stem cells 
Neural stem cells or neural precursor cells (NPC) contain the blueprint for 
constructing the individual cells of the CNS (Gage, 2000). The hardwiring 
of the connections between the network of neural cells is influenced by 
activity on the other hand. Early studies led to the isolation of progenitor 
cells with stem cell like capacities from the embryonic CNS and PNS 
(Reynolds et al., 1992). Thereafter, NPCs have been identified from 
various regions of the nervous system (Mignone et al., 2004). The isolation 
of NPCs from adult tissues opened up new avenues for the utilization of 
these pluripotent cells. Adult NPCs are found to reside in at least the 
hippocampus and the subventricular zone and in the spinal cord (Emsley 
et al., 2005). Much hope has been set on NPCs in the therapeutic field, 
and time will tell how successful they will be (Lindvall et al., 2004). Neural 
precursor cells have already shown some of their potential in modeling 
neurological disease (Jakel et al., 2004). Early studies reported the capacity 
of transdifferentiation of adult stem cells, including neural stem cells, but 
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recent studies have not succeeded in proving these claims (Galli et al., 
2000). However, stemness has also been described as a certain state of 
cells and the state would thus govern what the outcome of the cells is at 
later stages (Zipori, 2004). The creation of an appropriate niche remains 
precarious despite recent progress in the field (Shen et al., 2004). Thus, the 
true nature of stem cells is still warrants further delineation. 
Neural precursor cells can be isolated directly from embryonic or adult 
mammalian CNS by selecting cells responsive to mitogens. NPCs enrich in 
the presence of Epidermal Growth Factor (EGF) and Fibroblast Growth 
Factor (FGF) (Vescovi et al., 1999). These mitogens keep most of the 
NPCs undifferentiated. To increase the amount of undifferentiated human 
NPCs, Leukemia Inhibitory Factor (LIF) can be added to the culture 
(Wright et al., 2003), but is not obligatory for the enrichment of NPCs. 
Once the mitogens are withdrawed, the NPCs initiate differentiation. 
Differentiation can be expedited and instructed by various signals (see 
figure 3 for instructed differentiation of NPCs). Fetal Calf Serum (FCS) 
can be used for the generation of neurons and astrocytes from NPCs and 
IGF-1 instructs them to generate oligodendrocytes (Hsieh et al., 2004).
Figure 3. Differentiation of neurosphere cells by instruction of 
external factors. 
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Differentiation of NPCs isolated from the subventricular zone of postnatal 
day 7 mice has been studied in detail by transcript analysis, where distinct 
genetic programs of NPC differentiation were found (Gurok et al., 2004). 
Interestingly, that study found almost no overlap between genes identified 
from previous studies performed by different methods using rat derived 
NPCs (Zhou et al., 2001; Wen et al., 2002). Similar studies using fetal 
human samples have not been performed.  
Neural precursor cells have been utilized in the study of  Down syndrome, 
where the gene expression of neuronal target genes was analyzed with 
neurosphere derived material (Bahn et al., 2002). It was hypothesized that 
the disease mechanism of Down syndrome is present in the neural stem 
cells, where the authors describe a set of genes whose mRNA content was 
extremely low in the case neurospheres. This set of genes included 
transcription factors, adhesion molecules and synaptic components, all of 
which are concerned with neuronal maturation in some stage. All of the 
genes are also under the control of neuron-restrictive silencing factor 
REST (repressor element-1 silencing transcription factor). To test the 
validity of these results, the authors differentiated the neural stem cells, 
where only a diminutive proportion of the Down syndrome derived cells 
differentiated into neurons as compared to the controls. This study 
demonstrated the effect of neural stem cells in the investigation of 
developmental neurologic diseases. Fragile X syndrome has also been 
studied by the use of neural progenitor cells from an adult male with 
fragile X syndrome (Schwartz et al., 2005). The fragile X derived 
progenitor cells were cultured and differentiated into neuronal and 
astrocytic lineages. The expression of FMRP was reduced in neural cell 
culture in the patient as compared to the unaffected control, 
demonstrating the use of neural stem cells in the study of neurologic 
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diseases. Further studies using human neural stem cells are still under way 
and the true potential of neural stem cells in these are awaiting discovery.  
Regulation of gene expression 
Cell and tissue interaction during development relies on signaling. 
Hormones act over long distances, whereas paracrine factors influence the 
fate of their vicinity. The coordination of a group of cells changing the 
behavior of adjacent cells making them change in some way (eg 
differentiate) is termed induction. The proximate interactors are comprised 
of a limited set of proteins that the body uses for numerous processes. 
These proteins can be grouped into four major families based on their 
structures: (1) the fibroblast growth factor family (FGF)(Wilkie et al., 
1995), (2) the Hedgehog family (Ingham and McMahon, 2001), (3) the 
Wingless (Wnt) family (McMahon et al., 1992), and (4) the transforming 
growth factor beta superfamily (TGFbeta) (Kingsley, 1994). Tissue 
interactions have been intensely studied especially during tooth and kidney 
formation, where epithelial-mesenchymal interaction is central (Thesleff et 
al., 1989; Sariola et al., 1991). The response of a group of cells depends on 
its genome.
The regulation of gene expression is accomplished on several levels. Genes 
can be transcribed differentially, nuclear RNAs can be regulated by 
selection of which get into the cytoplasm and become mRNA, mRNAs 
can be selected for translation into proteins and proteins can be 
modificated differentially (Derman et al., 1981; Darnell, 1982). Differential 
gene transcription can be regulated by transcription factors and regulative 
elements.  
Transcription of genes is a highly regulated process controlling the 
interaction of transcription factors with cis-regulatory elements of DNA 
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and additional co-factors (Kadonaga, 2004). Trans-acting proteins bind cis-
regulatory elements and control the rate of transcription of individual 
genes. Transcription factors have proven to be central during development 
and it has been estimated that one transcription factor exists for ten genes 
in human (Levine and Tjian, 2003).  
Non-coding small endogenous RNAs have been discovered as important 
regulators of gene expression. The first small non-coding RNAs found 
were the small temporal RNAs lin-4 and let-7, identified in Caenorhabditis 
elegans as key regulators of developmental timing (Lee et al., 1993; 
Reinhart et al., 2000). According to current knowledge microRNA 
(miRNA) genes constitute about 1-2% of the known genes in human and 
miRNA genes are known to be important regulators of translation and 
stability of target mRNAs and it has been estimated that they regulate 
protein production for 10% of all human genes (John et al., 2004). 
Neuronal differentiation has been reported to be influenced by small, 
noncoding double-stranded RNAs where the mechanism appeared to be 
mediated by a dsRNA/protein interaction (Kuwabara et al., 2004). The 
involvement of miRNAs have also been implicated in diseases such as 
Spinal Muscular Atrophy and Fragile X syndrome (Caudy et al., 2002; 
Ishizuka et al., 2002; Dostie et al., 2003). 
Regulation of gene expression is a context dependent dynamic process 
that requires the interaction of several proteins. Transcription factors can 
both activate and repress the transcription of any given gene determined 
by the surroundings and its own concentration and physical form (Ma, 
2005). The expression of a large number of genes can be studied by 
microarray methods. RNA microarray studies have proven their validity in 
global transcript analysis in many different fields from study of 
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pathogenesis to classification of malignancies and diseases (DeRisi et al., 
1996; Pomeroy et al., 2002). 
HUMAN GENETICS 
The human haploid genome contains 3 billion base pairs of DNA 
harbored in 22 autosomal and one sex chromosome. DNA is also present 
in mitochondria in addition to the chromosomes. Variations in DNA may 
contribute to disease and based on the role of genetic factors the diseases 
can be roughly divided into categories: (i) monogenic disorders, (ii) 
multifactorial disorders, (iii) mitochondrial disorders, (iv) chromosomal 
aberrations and (v) aquired somatic genetic disorders. Our present 
understanding of genetics lies on the foundations of work by Gregor 
Mendel, who studied the inheritance of genes in the garden pea, 
establishing the basic laws of inheritance (Mendel, 1866). Experiments by 
Oscar Avery showed that a nucleic acid was the chemical basis for specific 
heritable transformations in bacteria (Avery et al., 1943). Avery’s discovery 
sparked research into the nature of DNA and almost a decade passed 
before Francis Crick and James Watson discovered the chemical structure 
of DNA which by the order of its bases, encodes the genes (Watson and 
Crick, 1953). Watson and Crick based their proposal of the DNA structure 
on the work of Rosalind Franklin who had used X-rays to discover that 
DNA had phosphate groups on the outside and that DNA existed in two 
forms (Maddox, 2003). 
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The Human Genome Project 
The Human Genome Project (HGP) was initially launched in 1990 with 
the goal to obtain the euchromatic sequence of the human genome. The 
initial approach was biphasic, with mapping of the human genome to 
provide a scaffold for genome assembly and subsequent sequencing 
(Bentley et al., 1998; Deloukas et al., 1998). To facilitate and confirm the 
mapping approach, both human and mouse genomes were mapped and to 
gain knowledge before the actual sequencing effort, smaller and less 
complicated genomes were sequenced (Goffeau et al., 1996; Adams et al., 
2000; Waterston et al., 2002). While the approaches gained success, the 
ultimate goal seemed within reach and finally, in February 2001, the 
International Human Genome Sequencing Consortium and Celera 
Genomics both provided a draft sequence as a first overall view of the 
human genome (Lander et al., 2001; Venter et al., 2001).  
Both reported draft sequences were far from complete and the finished 
sequence was published three and a half years later (Consortium, 2004). 
Although this sequence was published as complete, covering 99% of the 
euchromatic genome, it still contained gaps and requires further 
complementation. Most of the gaps are associated with segmental 
duplications requiring novel methods for solving them. 
The HGP opened the door to a new era in biomedical research, where a 
collaborative effort generated and characterized systematically a vast 
domain of biological knowledge. However, as most knowledge paves way 
for further questions, does the sequence lay several challenges ahead. All 
genetic polymorphisms need to be systematically identified to enhance 
their role in the study of diseases. Every functional element, including 
genes, proteins, regulatory controls and structural element needs 
systematic characterization and annotation. And finally, the functional 
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modules for genes and proteins need systematic identification. These 
issues require the comprehensive studies of numerous human genomes, 
comparative analyses with additional genomes and improved 
comprehension of expression, localization and interaction of functional 
modules.
Positional cloning to find disease genes 
Identification of disease genes based on their location in the genome is 
called  positional cloning (Collins, 1992). The approach consists of several 
steps, starting off with definition of the disease phenotype and collection 
an appropriate family material, followed by a genome wide scan and the 
identification of the disease susceptibility locus by linkage methods, 
advancing to linkage disequilibrium and haplotype mapping to further 
define the disease locus. The first human gene behind a genetic disease 
identified by a positional cloning effort was chronic granulomatous disease 
in 1986 (Royer-Pokora et al., 1986; Royer-Pokora et al., 1986), but 
positional cloning became a standard procedure only several years later 
(Collins, 1995). The late 1980s witnessed the evolution of the needed 
technologies e.g. polymerase chain reaction and the HGP for high 
throughput positional cloning (Saiki et al., 1985; Mullis et al., 1986; Collins 
and Galas, 1993).
In genetic mapping, loci in the genome are studied in relation to each 
other. Two genetic loci are linked if they are inherited together more often 
than expected by chance. Linkage analysis tests two assumptions; two loci 
are linked with a given recombination fraction or they are not linked. The 
result of linkage analysis is expressed as a lod score, meaning the logarithm 
to the 10 base of the ratio of the two assumptions tested in linkage 
analysis. Linkage disequilibrium denotes the non-random distibution of 
alleles at linked loci. In linkage disequilibrium, the region adjacent to a 
disease marker will be overrepresentated by a specific allele. In the disease 
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chromosomes, the length of the chromosomal region in linkage 
disequilibrium depends on both the age of the mutation and the 
recombination frequency of the region of interest (Peltonen et al., 1995). 
Linkage disequilibrium offers shortcuts in the localization of disease genes 
in consanguineous families and in the search for chromosomal segments 
in isolated founder populations (Nikali et al., 1995). When the disease 
locus has been mapped, positional candidate genes are identified from the 
genomic sequence and positional cloning ends in the identification of the 
disease associated mutation. Prior to the availability of genomic sequences, 
an intermediate step of physical mapping was needed to establish a frame 
for identification of positional candidate genes.  
The HGP initiated with the mapping of the human and mouse genomes to 
facilitate the study of inherited diseases in addition to providing the 
scaffold for sequencing. The building of physical maps in the late 1990s 
utilized the isolation of artificial chromosome clones in the form of Yeast 
Artificial Chromosomes (YAC) (Burke et al., 1987), P1-Artificial 
Chromosomes (PAC) (Ioannou et al., 1994) and Bacterial Artificial 
Chromosomes (BAC) (Shizuya et al., 1992). The process begun with 
physically mapping these clones to the desired chromosomal region and 
thereafter organizing the clones relative to each other. A well utilized 
technique was Fluorescence In-Situ Hybridization, where the discovery of 
the use of extended DNA fibers paved way for increased resolution of the 
physical maps (Heiskanen et al., 1995). The ends of the clones were 
sequenced, which aided in the positioning of first candidate genes to the 
critical DNA region. As the HGP accelerated and made progress, 
preliminary sequences became available for gene prediction. Ab initio gene 
prediction software were set to high sensitivity and thus initial estimates of 
gene number in the genome may have been overly optimistic. In addition 
to gene prediction, the obtained genomic sequences were used for 
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construction of novel polymorphic genetic markers, which then might 
help in the further restriction of the targeted genetic region. As the 
physical map of the critical DNA region was finished, positional candidate 
genes were analyzed for disease associated mutations by way of e.g. 
motility assays, sequencing and expressional analyses.  
Nowadays positional cloning could be denoted a positional candidate gene 
approach, as the regional candidate genes are well listed in the databases 
and can be directly analyzed based on their position under the linkage 
peak.
At times, the disease gene identification by positional cloning is not as 
straightforward as expected. Consequences of the mutations in non-coding 
regions are more difficult to detect than those found in coding regions of 
the DNA. A good example of such a mutation was the Finnish founder 
mutation in diastrophic dysplasia, a GT-to-GC transition in the donor 
splice site of the 5-prime untranslated exon of the disease gene. The 
mutation acts by severely reducing mRNA levels (Hastbacka et al., 1994; 
Hastbacka et al., 1999). Duplications and larger inversions may lead to the 
disruption of a gene or its regulatory element (Chen et al., 2004). Large 
chromosomal rearrangements are well documented to be associated to 
monogenic chromosome abnormalities and malignant transformation 
(Kolomietz et al., 2002). Hence, caution should be exercised when 
excluding mutations by traditional methods as they may not expose these 
alternative mechanisms behind the disease. 
The Finnish Disease Heritage 
In the light of current knowledge, the ancestors of the modern Finns have 
arrived both from eastern Ural some 4000 years ago and from a more 
31
stable immigration of groups arriving from the South and West during 
some thousand years (Kittles et al., 1998; Norio, 2003). During centuries, 
the forefathers inhabited the coast lines, and only during the 16th century 
did the migration reach the northern parts of Finland as the Swedish king 
Gustavus Wasa ordered migration to populate especially the Russian 
border (Cornell et al., 1966). Internal immigration was also propulsed by 
the need for new land and the avoidance of taxation by the Crown. The 
slow migratory movements in a proportionally vast country lead to the 
emergence of small regional isolates and village societies. Thus, the 
relatively small gene pool of the ancestors was spread unevenly, and lead 
finally to the regional clustering of  heterozygote disease gene carriers and 
the incidence of autosomal recessive diseases in their offspring. Random 
drift was powerful in small founder populations, while some mutations got 
enriched, the incidence of others declined markedly. 
In a genetic isolate, one mutation can be assumed behind each disease that 
has enriched in the population. In other words, the genetic region of a 
distinct disease is derived most often from one early Finn carrying the 
gene defect in his or her genome. This leads to a definitive technical 
advantage in the identification of mutations behind rare diseases using the 
Finnish genome. The peculiar enrichment of mostly autosomal recessive 
diseases (carrying one major mutation in the Finnish genome) became 
known as the Finnish Disease Heritage. Early reports deviated from 
today’s criteria of the FDH. Poverty and socioeconomic factors leading to 
inadequate hygienic conditions in prewar Finland in the 19th and 20th
century were reasons for high prenatal mortality. Thus, diseases leading to 
early childhood death were not recognized as own entities. Still, diseases 
that belong to the modern FDH-definition, such as Diastrophic Dysplasia 
were described (Lahdensuu, 1939). However, some of the diseases thought 
to have enriched in Finland (Gripenberg, 1953), were in reality prevalent 
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due to non-genetic causes. The first publications containing the FDH 
steps, the so called Perheentupas steps, appeared in the 1970s (Norio et al., 
1973).
Examples of success stories where the Finnish genome has been utilized 
to study the pathomechanism of disease include Polycystic 
lipomembraneous osteodysplasia with sclerosing leucoencephalopathy 
(Paloneva et al., 2002; Klunemann et al., 2005) and variant late neuronal 
ceroid lipofuscinosis (Savukoski et al., 1998; Holmberg et al., 2004). PLO-
SL is good model for frontal lobe dementia and is intriguing due to 
mutations in two genes part of the same signaling cascade. VLINCL on 
the other hand represents a disease with a fairly young mutation where 
most families originate from a small village society in southern 
ostrobotnia.  
Nowadays the Finnish Disease Heritage is composed of 36 disorders 
(Norio, 2003). The genetic loci has been established for 34 of these and 
the gene has been characterized for 33 (www.findis.org). The FDH 
contains two lethal arthrogryposes, Lethal Congenital Contracture 
Syndrome (LCCS) and Lethal Arthrogryposis  with Anterior Horn Cell 
Disease (LAAHD), which have not been so far found elsewhere. 
LETHAL ARTHROGRYPOSIS 
Arthrogryposis is derived from the Greek words arthron for joint and 
gryposis for crooked and is used to describe the phenotype of joint 
contractures. Lethal arthrogryposis is a clinical description of a phenotype 
of heterogeneous etiology. It represents the end-point of akinesia during 
pregnancy and can be due to neurological, connective tissue or extrinsic 
reasons schematically presented in figure 4 (Moessinger, 1983). The 
33
descriptive findings consist of distinct facial features, joint contractures 
and a short umbilical cord. The facial features include an expressionless 
face, a petite mouth, a small receding chin and lowset poorly lobulated 
ears. Autopsy reveals pulmonary hypoplasia. At times, the joint 
contractures are accompanied by pterygia (Hall, 1986). The severity of the 
features depends on the time of onset of the fetal akinesia during 
pregnancy (Moerman et al., 1990). 
Epidemiology 
Estimations of the frequency of arthrogryposis in different populations 
have been variable depending on the definition of the condition and the 
type of study. Multiple congenital contractures (arthrogryposis) has been 
estimated to occur with a frequency of about 1:3000 live births and about 
1 in every 200 newborns is estimated to be born with some form of 
contractures (Hall, 1997; Hall, 2002). Silberstein and co-workers reported a 
birth prevalence of 1 in 12000 for arthrogryposis multiplex congenita in 
Western Australia from a cohort born between 1980-1993 (Silberstein and 
Kakulas, 1998). Darin and co-workers reported the birth prevalence to be 
1 in 5100 in a cohort from western Sweden born between 1979 and 1994 
(Darin et al., 2002). However, none of these studies encountered very early 
onset forms associated with lethality in utero.  
Figure 4. Development of the Fetal Akinesia Deformation Sequence 
according to Spranger et al 1982 
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The incidence of anterior horn cell disorders associated with 
arthrogryposis and early fetal demise is poorly known. In one study from 
Finland, the incidence of LCCS only was estimated to be 1:12 700-1:19 
000 births (Vuopala and Herva, 1994). In another study on LAAHD, a 
rough estimate of the incidence  to be at least 1:50 000 was given (Vuopala 
et al., 1994). SMN-gene analyses were not done. The figures for all types 
of  anterior horn cell diseases with arthrogryposis are lacking. 
Pathogenesis
The reasons behind intrauterine fetal akinesia can be both intrinsic and 
extrinsic. The clinical picture remains fairly uniform despite the great 
number of conditions causing the disorder. Multiple explanations for this 
exists. Normal joint and adjacent tissue development is dependent on 
active fetal mobility (Drachman and Coulombre, 1962). As the joints 
become immobile, extra connective tissue develops around the joint, 
further limiting joint movement (Hall, 1997). The length of the umbilical 
cord is dependent on the proportion to the tractile tension which varies 
according to fetal size and mobility (Katsumata et al., 1991). Both fetal 
breathing and the volume of amniotic fluid are critical to the development 
and growth of the lung (Wigglesworth, 1997). The facial features are 
thought to be caused by disturbed fetal swallowing that accounts for the 
hypoplastic jaw (Moessinger, 1983). The ear abnormality stems from 
defective muscle function in the small ear muscle (Zerin et al., 1982). 
Fetal causes to akinesia can be grouped into anatomical locations: (I) 
muscular defects, (II) neuronal disorders and (III) connective tissue 
defects (Spranger et al., 1982; Moerman et al., 1990). The most common 
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cause to fetal akinesia and lethal arthrogryposis is neuronal dysfunction 
(Banker, 1986; Hageman et al., 1987; Hall, 1997).  
External causes of arthrogryposis can be divided into: space limitations, 
intrauterine circulation and maternal disorders (Hall, 1997).  
Lethal Congenital Contracture Syndrome 
Lethal Congenital Contracture Syndrome is a fetal motoneuron disease 
characterized by the Fetal Akinesia Deformation Sequence (Spranger et al., 
1982). The fetuses are small for gestational age (<2SD) and present with a 
typical arthrogryposis phenotype (fig 5 displays a 23 week old LCCS fetus 
with all phenotypic features) consisting of multiple joint contractures, 
skeletal muscle atrophy with stick-like extremities, distinct facial features 
and hydrops (Herva et al., 1985). The facial features consist of ocular 
hypertelorism, lowset and posteriorly angulated ears and a hypoplastic jaw. 
Tissue pathology is characterized by severe muscle atrophy, lung 
hypoplasia and degeneration of the anterior horn of the spinal cord as the 
hallmark of the syndrome (see fig 6). The CNS is normal above the 
decussatio pyramidalis as compared to age-matched controls (Herva et al., 
1988). The skeletal muscle atrophy is considered neurogenic as embryonic 
and neonatal myosin heavy chain (MHC) isoforms are expressed, but the 
intrafusal muscle spindles are lacking. Motor innervation is needed for 
differentiation of intrafusal fibers (Soukup et al., 1990; Soukup et al., 1993) 
and the lack of intrafusal fibers support the idea of defective motoneuron 
innervation in LCCS (Vuopala et al., 1996). Fetal akinesia and hydrops can 
be observed in early sonography during pregnancy, and LCCS invariably 
leads to death of the affected fetuses before the 32nd gestational week. The 
incidence of LCCS has priorly been estimated to 1:19000 in Finland. LCCS 
is inherited in the autosomes, recessively. 
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The changes in LCCS spinal cord have been interpreted as degenerative, 
with the demise of motoneurons partly overlapping the period of natural 
spinal PCD. Indeed, LCCS is most often initially recognized due to fetal 
immobility during ultrasound examinations. The reason for prenatal death 
of LCCS fetuses remains unknown, but may depend on evolutionary 
factors.
Figure 5. LCCS fetus displaying all 
the characteristic features including 
distinct facial features, multiple 
contractures and atrophic muscles.
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Lethal Arthrogryposis with Anterior Horn Cell Disease 
Lethal Arthrogryposis with Anterior Horn Cell Disease (LAAHD) shares 
many similarities to LCCS. The fetuses may survive delivery, but die within 
one month. The neuropathological findings closely resemble those of 
LCCS. The locus for the LAAHD gene is currently unknown, but it is also 
inherited in the autosomes recessively (Vuopala et al., 1996). The incidence 
of LAAHD is at least be 1:50 000 in Finland (Vuopala et al., 1995). 
Figure 6. Histological sections of LCCS and age-matched controls of 
quadriceps femoris muscle and lumbar spinal cord. In the upper row are 
sections from a 23+4 week LCCS fetus shown, the lower row displays identical 
sections from the age-matched control. LCCS muscle shows scattered 
myotubes without clear organization. The spinal cord shows marked reduction 
at the anterior part with degeneration of the ventral and lateral columns 
(Pakkasjärvi et al, 2005). 
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Spinal Muscular Atrophy type I 
The neuropathological findings of LCCS resemble those of type I Spinal 
Muscular Atrophy (Hoffmann, 1893; Werdnig, 1894; Emery, 1971; Pearn, 
1980). SMA type I is the most common autosomal recessive 
neurodegenerative disorder of childhood. It is at times encountered with 
artrogryposis. SMA is characterized by degeneration of motoneurons 
associated with muscle paralysis and atrophy. The most common form of 
SMA involves defects in the SMN-gene on chromosome 5q, where the 
severity of the disease depends on the defects in the neighboring NAIP-
gene (Lefebvre et al., 1995; Mahadevan et al., 1995; Roy et al., 1995) and is 
at times associated with fetal arthrogryposis. Deletion of both copies of 
the SMN genes and the NAIP gene leads to most severe form of SMA 
designated SMA-0 (Burglen et al., 1996). The SMA-disease spectrum has 
proven to be heterogenic, and distinct entities can be found in SMA with 
pontocerebellar hypoplasia, and SMA caused by defects in the IGHMBP2-
gene leading to SMA with early diaphragmatic affision called SMARD1 
(MIM 604320), which usually is encountered with arthrogryposis (Rudnik-
Schoneborn et al., 2003). One x-chromosomal form is also known that 
presents with arthrogryposis (Greenberg et al., 1988).
The incidence of SMA in Finland has been estimated to 1:15 000 (Ignatius, 
1992).
MOTONEURON DISEASES 
Amyotrophic Lateral Sclerosis (ALS) is the most common motoneuron 
disease. The hallmark is the dysfunction and death of neurons in the 
motor pathways leading to spasticity, hyperreflexia, generalized weakness, 
muscle atrophy and paralysis (Mulder et al., 1986). ALS is clinically and 
genetically heterogeneous. Linkage has been found to several genetic loci 
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for familial ALS, which constitute about 5-10% of cases (Hand and 
Rouleau, 2002). Several predisposing genes have also been identified to the 
most common sporadic form of ALS. Among the familial cases, some 
20% are associated with mutations in the Cu/Zn superoxide dismutase 
(SOD1) on chromosome 21q22.1 (Rosen et al., 1993). Sporadic cases are 
occasionally also encountered with novel mutations in SOD1 (Jones et al., 
1993). Susceptibility is further associated with deletions or insertions in the 
gene encoding the heavy neurofilament subunit NEFH (Figlewicz et al., 
1994), by deletions in the gene encoding peripherin PRPH (Gros-Louis et 
al., 2004) or by mutations in the dynactin DCTN1 (Munch et al., 2004). 
Several other ALS loci have also been identified. The gene mutated in 
ALS2, resides on chromosome 2q33 (Hadano et al., 2001; Yang et al., 
2001), ALS3 on chromosome 18q21 (Hand et al., 2002), juvenile ALS or 
ALS4 on chromosome 9q34 in relative proximity to the LCCS region 
(Chen et al., 2004). ALS5 is linked to chromosome 15q15-q21 (Hentati et 
al., 1998), ALS6 to chromosome 16q12 (Abalkhail et al., 2003; Ruddy et 
al., 2003), ALS7 to chromosome 20q13.33 (Sapp et al., 2003) and ALS8 to 
chromosome 20q13.33 (Nishimura et al., 2004; Nishimura et al., 2004).  
Motoneuron diseases have sometimes been described as systemic diseases 
with primary manifestation in the spinal cord. What then makes 
motoneurons so vulnerable to extrinsic noci? Motoneurons are large post-
mitotic cells that can extend the axons in length over 1m. They have a high 
metabolic rate and their cytoskeletons face large demands to sustains 
stresses encountered (Cookson and Shaw, 1999). Motoneurons possess 
large amounts of glutamate receptors and they lack calcium binding 
proteins and they express high levels of SOD1 rendering them vulnerable 
to oxidative stress (Shaw and Ince, 1997). So in addition to the complex 
and delicate development of motoneurons, they contain special features 
which makes them vulnerable to cell death.  
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3. AIMS OF THE STUDY 
I. Localize the LCCS gene in well characterized Finnish 
families to a chromosomal region 
II. Characterize the critical DNA-region and analyze the 
candidate genes for the disease mutation 
III. Decipher the molecular pathways disturbed in the 
pathogenesis of LCCS 
IV. Study the development of neurons and cells of glial 
lineage and the role of neural stem cells during 
pathogenesis of LCCS 
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4. MATERIALS & METHODS 
All methods and materials applied to this thesis are listed below and 
sited according to the original publications in which they appear. 
Ethical considerations
All samples were collected after written informed consent from the 
parents. The project has been approved by the ethical committee of 
Helsinki University Central Hospital, Hospital District of Helsinki and 
Uusimaa, and all work has been done in accordance with the Helsinki 
declaration.
Patients
Initially, the family material consisted of 15 Finnish LCCS families, a total 
of 68 individuals, of whom 26 were affected. During the course of the 
study  13 new cases were included. The diagnosis of patients with LCCS 
has been confirmed in autopsy and histologic examination of the spinal 
cord. The material used in each publication is presented in the respective 
materials section of the corresponding work. 
The LAAHD family material consisted of 6 Finnish families, a total of 14 
individuals, of whom 6 were affected. No new cases were included during 
the study. All of the LAAHD patient DNA was isolated from paraffin 
embedded sections. The diagnosis of LAAHD patients has been 
confirmed in autopsy and histologic examination of the spinal cord. 
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Method     Original Publication
DNA marker analysis    I 
Linkage analysis     I 
Linkage Disequilibrium Analyses   I 
Fluorescence In Situ Hybridization  I 
DNA Sequencing    I 
RNA Isolation     II, III 
Genechip Processing    II, III 
Gene Expression Data Analysis   II, III 
cDNA Synthesis    II 
Reverse Transcriptase-PCR   II, III 
Real Time Reverse Transcriptase- PCR  II 
Transcription Factor Analysis   II 
Neural Precursor Cell Culture   III 
Cryopreservation    III 
In Vitro Differentiation of Precursor Cells III 
Immunocytochemistry    III 
Apoptosis assay     III 
Proliferation assay    III 
Methods not described in the individual publications are presented 
below:
Bacterial clone contig 
The PAC (Pieter de Jong, Roswell Park Cancer Institute, Buffalo, NY) and 
BAC (Genome Systems Inc.) libraries were screened by PCR using primers 
for known polymorphisms and STSs in the region. New markers were 
generated by chromosomal walking. Positive clones were colony purified 
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and grown overnight in TB in the presence of the appropriate antibiotic. 
DNA was extracted by alkaline lysis.  
Radiation Hybrid mapping 
A whole genome radiation hybrid (rh) panel was analyzed (Research 
Genetics). Markers were amplified by PCR from each rh well. PCR was 
performed according to standard procedure and products were visualized 
on 1-2% agarose gels. The screening results for the panel were analyzed by 
the application of the rh server at stanford human genome center. 
Computational analyses 
The genomic sequence for the critical region was analyzed in sections by 
accessing individual programs Genscan (Burge and Karlin, 1997), Genie 
(Kulp et al., 1996), MZEF (Zhang, 1997) and Grail (Xu et al., 1994) in 
addition to the Genotator workbench (Harris, 1997), which represented 
the initial version of the current Genomebrowser (Karolchik et al., 2003) 
and Ensembl-platforms (Hubbard et al., 2002). MiRNA prediction was 
performed by accessing the mirSeeker server (Lai et al., 2003). In addition, 
sequences were compared using the basic local alignment search tool 
BLAST (Altschul et al., 1990). Sequences were also aligned locally using 
the Sequencher software (Gene codes, Inc.).  
Northern blot analysis 
PolyA+ RNA was isolated from skin fibroblasts, CNS biopsies, liver 
biopsies,  lung biopsies, kidney biopsies or muscle biopsies of post-
mortem LCCS fetuses and compared to RNA from similar tissues of age-
matched control fetuses aborted for social reaseons. 5ug of polyA+ RNA 
was electrophoretically separated in a 0.8% agarose gel in the presence of 
formaldehyde and blotted onto a nylon membrane. Northern 
hybridizations were performed at 65C utilizing Express Hyb hybridization 
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solution (Clontech). RT-PCR products were processed  to be used as 
probes according to standard protocols. 
Epidemiology
To attempt a complete ascertainment, we collected information from 
multiple independent sources to identify all fetuses and infants affected 
with arthrogryposis in Finland between years 1987-2002. Information was 
collected from all live births, stillbirths and terminated pregnancies having 
the diagnosis or cause of death  3350A-3359X and 7558A (International 
Classificafion of Diseases-9), and G12.0-G12.9 and Q74.3 (ICD-10), 
respectively, corresponding to the diagnoses of spinal muscular atrophy or 
anterior horn cell disease or arthrogryposis.  
The following sources were used: 
1) The death certificates of children who died before 12 months of age in 
Finland during 1987-2002
2) The National Registry for Congenital Malformations in Finland which 
also receives data on all terminated pregnancies (ref. www.stakes.fi)  
3) All seven Departments of clinical genetics in Finland (five university 
hospitals (Helsinki, Turku, Tampere, Kuopio and Oulu), The Finnish 
Family Federation (Väestöliitto) and The Folkhälsan Department of 
Medical Genetics)  
4) The five University hospital residential and outpatient registers 
5) All those cases that had been analyzed for SMN-gene deletions at the 
department of medical genetics, University of Turku were listed. SMN-
gene testing became available in Finland in 1996 and the laboratory of 
Turku has been the only diagnostic laboratory for SMA in Finland. 
In addition, further cases were looked for at the registers of the 
perinatalogy units as well as at the autopsy and muscle biopsy registers of 
the departments of paediatric pathology of the five university hospitals. 
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The National Research and Development Centre for Welfare and Health 
(STAKES) maintains a nationwide register with data on all malformations 
from live births and stillbirths in Finland that are diagnosed or suspected 
in children under 12months of age, or in terminated pregnancies. The 
information on malformations is continually updated nationwide.  
For all cases found, the clinical, laboratory, autopsy and ultrasonic data 
were re-evaluated. All cases with death in utero or before 12 months of 
age were included in the original cohort. Arthrogryposis was defined as 
joint contractures present in at least two regions of the body as seen at 
clinical examination or autopsy. 
For incidence calculations, numbers of livebirths and stillbirths for years 
1987-2002 were obtained from the Central Statistical Office of Finland.  
Birth prevalence was defined as number of cases (live births or stillbirths) 
per total number of births (including live births and stillbirths). 
Incidence was defined as total number of cases (live births, stillbirths, 
intrauterine deaths and terminated pregnancies) per total number of births.  
Lethal arthrogryposis was defined as arthrogryposis with survival under 12 
months of age.  
This study was approved by the ethical committee of Helsinki University 
Central Hospital, Hospital District of Helsinki and Uusimaa, and all work 
has been done in accordance with the Helsinki declaration. Approval for 
re-evaluation of patient records and analysis of the registrys from 
STAKES (the National Research and Development Centre for Welfare 
and Health), and the death certificate records from the Central Statistical 
Office of Finland was given by the Ministry of Social Affairs and Health. 
46
5. RESULTS AND DISCUSSION 
Linkage studies – Search for shared chromosomal regions and 
assignment of the LCCS locus to chromosome 9q34.1 
(Publication I + unpublished) 
LCCS shows enrichment in the genetically isolated subpopulation of the 
late settlement area of Finland (Vuopala and Herva, 1994). Therefore, the 
disease can be assumed to be caused by a single major mutation and 
linkage disequilibrium can be utilized in the final positioning of the gene 
(Hastbacka et al., 1992). Thus, the search for a shared chromosomal 
segment was used as the method to find the disease locus. We genotyped 
five affected individuals from two families, but found no evidence for a 
shared haplotype on any chromosomal region The haplotypes of the two 
affected siblings from family nr 2 (shown in publication I) used in this 
study were, however, identical by descent (IBD) for a total of 18 
chromosomal regions and the siblings in family nr 3 were IBD for eight 
regions. (Two alleles are identical by descent when the identical allele is 
found in an earlier generation without any intervening mutations) Four of 
the identified IBD-regions were located in the same chromosomal regions. 
Linkage analysis using dense marker maps on those regions with the 
complete family material revealed evidence for linkage between LCCS and 
chromosome 9 markers. The maximum pairwise LOD score of 4.7 was 
obtained with marker D9S61. Obligatory recombinations restricted the 
LCCS locus to a 4cM interval between markers D9S1825 and D9S1830.  
The LAAHD family material proved to be insufficient for linkage studies 
or exclusion of this chromosomal locus.
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Haplotype mapping to fine map the critical DNA region 
(Publication I, unpublished) 
Population isolates are beneficial for fine mapping of disease loci and the 
applicability of the haplotype mapping in the process aiming at the 
restriction of the critical DNA region. Limited numbers of recombinations 
have occurred in the original founder chromosome rendering the founder 
haplotype conserved in modern chromosomes. In the case of LCCS, 
haplotype mapping was utilised to significantly restrict the disease locus. 
Initial proof of linkage restricted the critical DNA-region to a vast stretch 
of DNA on chromosome 9q33-34. Extended haplotypes were built in the 
region to further restrict the critical region. The ancient recombinations 
observable on the core haplotype defined the critical region between 
markers D9S904 and D9S61, which was subsequently analysed in details 
for candidate genes. However, new markers derived from the 
accumulating sequences produced by the HGP and finer mapping and re-
evaluation of the diagnoses eventually lead to the restriction of the LCCS 
locus to the adjacent region between markers D9S1827 and D9S752 (the 
positional relations of the critical region markers are depicted in figure 7). 
Sequencing of candidate genes was expected to yield at least novel 
polymorphisms to be utilized for haplotype mapping, but thus far, only a 
small amount of single nucleotide polymorphisms (SNP) were identified 
from the coding sequences of the analyzed candidate genes. 
Figure 7. Physical relationships of the critical region markers
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Physical mapping (Publication I + unpublished) 
Linkage-based mapping of LCCS was concluded in 1998, during which the 
genome project was underway. The physical maps for the 9q34 region 
were non-existent and, thus initially a physical map for the region between 
markers D9S904 and D9S61 was constructed by PAC and BAC-maps. 
The clones were ordered mainly by FISH-methods as described 
previously. For certain markers, radiation hybrid-mapping was applied. 
The coverage for the PAC-library and a commercial BAC-library was not 
sufficient for the region and a collaboration with the Sanger Centre was 
established to obtain clones for the region from the RPCI-11 BAC library 
(Osoegawa et al., 2001). This collaboration yielded a complete physical 
map for the critical LCCS region and subsequently also the genomic 
sequence. The orientation of the individual genomic clones in relation to 
each other was still confirmed by STS-mapping (sequence tagged site) and 
a scaffold for candidate gene identification was established. At the time, an 
identical physical map was constructed by the HGP, but it did not increase 
the resolution or information content for the LCCS locus.  
Candidate genes (Publication I + unpublished) 
Initial positional candidate genes (NGAL, Notch1) were mapped by 
metaphase-FISH. By the construction of the physical map, further 
candidate genes were located in the critical region and analysed as 
candidate genes. As the genomic sequences were finished, a detailed 
transcript map for the region was obtained and candidate genes (see table 
1) were sequenced through systematically to detect the causative mutation 
for LCCS. The structure of the candidate genes were based on published 
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cDNA or genomic sequences, which are continually updated online. The 
region contained several interesting positional and functional candidate 
genes including Dynamin-1. Dynamin-1 was considered the perfect 
candidate gene as it was functionally  in line with the clinical picture of 
LCCS (van der Bliek et al., 1993). Namely, a temperature sensitive 
Drosophila mutant of Dynamin-1 designated Shibire showed paralysis at 
permissive temperatures (Clark et al., 1997). Homozygous mammalian 
mutations were suspected to be embryonically lethal (van der Bliek, 
personal communication). Dynamin-1 was involved in the recycling of 
endocytic vesicles in the synapse, where the role of the proteins is thought 
to be to cut off the throat of the budding vesicle (Sweitzer and Hinshaw, 
1998).
Another good regional and functional candidate gene was Syntaxin 
binding protein 1 (STXBP1), which was localized to the critical region by 
sequencing the ends of physical clones in the region (Swanson et al., 1998). 
STXBP1 resided reasonably close to Dynamin-1. It is involved in the 
localization of synaptic vesicles in the synapse (Verhage et al., 2000). It is 
similar to Endophilin B2 (SH3GLB2) located more telomeric in the critical 
region (Pierrat et al., 2001). The mouse model with a defective STXBP1 
gene dies at the time of birth, it is paralyzed, but the brain is normally 
developed (Verhage et al., 2000). Hence, close resemblance to the LCCS 
phenotype can be observed. The other positional candidate genes did not 
evidently present as functional candidates, but were sequence analyzed in 
due order. However, none of the coding sequences of the positional 
candidates presented with mutations causative for LCCS. 
To provide further evidence for the exclusion of the positional candidate 
genes, we verified their expression levels and transcript sizes by reverse 
transcriptase PCR and/or Northern blotting. RNA from different tissues 
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and patients of different ages were selected to exclude possible 
developmental stage dependent variations. No differences between 
patients and controls could be detected in the steady state transcript level 
of the regional genes. 
As previously noted, non-coding small endogenous RNAs have been 
proposed as key regulators of developmental timing. We sought to identify 
potential miRNA genes in the critical LCCS region by the application of 
the mirSeeker software (Lai et al., 2003). Multiple putative miRNA clusters 
were identified, which we subsequently analyzed for mutations. 
Unfortunately however, no disease associated mutations were revealed by 
this approach. This does not exclude the role of miRNA genes in the 
molecular pathogenesis of LCCS, as the identification of miRNA genes is 
still developing. Further, regulatory regions in the noncoding regions also 
demand additional studies. Thus, the next task is to analyze the whole 
critical region genomic DNA. The mutation can be in the regulatory 
regions of a gene, which can reside relatively far away from the coding 
region (Kondo and Duboule, 1999). Hence, the identification of the LCCS 
mutation will provide interesting times for future work. 
Gene Full name 
LCN2 Lipocalin2 
STXBP1 Syntaxin binding protein 1 
ZNF-X Zinc Finger X transcription factor 
DNM-1 Dynamin-1 
KIAA1069 Novel gene 
CCBL Cysteine Conjugate Beta-Lyase 
SPTAN brain Spectrin alpha/Fodrin 
ZYG ZYG-11 Homolog B 
Endog Endonuclease G 
VSN Novel gene 
SH3GLB2 Endophilin B2 
Table 1:
Full genes excluded by sequencing and expression analysis as causative of LCCS 
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CEECAM cerebral endothelial cell adhesion molecule 1 
DOLPP1 dolichyl pyrophosphate phosphatase 1 
CRAT carnitine acetyltransferase 
LRRC8 LEUCINE-RICH REPEAT-CONTAINING PROTEIN 8 
PHYHD1 phytanoyl-CoA dioxygenase domain containing 1 
IER5L Immediate early response gene 5L 
PPP2R4 Phosphotyrosyl phosphatase activator 2A 
Revised diagnostic criteria and incidence figures for LCCS 
(unpublished) 
Since no mutations in the critical 9q34.1 region genes were verified, a re-
evaluation (clinical features, gestational anamnesis, family history, genetic 
mapping) of all patients was performed. Combining clinical data with the 
extended haplotypes identified two fetuses that differed from the majority 
of patients. These two cases survived beyond the 32nd gestational week and 
also restricted the critical DNA region differently from the other patients. 
When these two cases were omitted from the haplotype mapping, the 
region could be pinpointed more accurately between markers D9S1827 
and D9S752. This process generated new diagnostic criteria for LCCS: (i) 
total immobility during pregnancy, (ii) death before 32nd gestational week, 
(iii) typical verified spinal cord neuropathological findings and (iv) muscle 
atrophy in addition to the typical phenotype. Special emphasis should be 
laid on the fetal akinesia and prenatal death, as both excluded cases 
survived beyond this period and had recorded fetal movements in the 
13week ultrasound examination.  
To clarify the true number of LCCS cases in Finland and to derive revised 
incidence figures, a register based study was initiated. Information on all 
fetuses and infants affected with arthrogryposis in Finland between 1987-
2002 were collected from multiple independent sources. During this time 
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period, a total of 214 cases, live births, stillbirths, intrauterine deaths or 
terminated pregnancies having the diagnosis of arthrogryposis were found. 
Of these, 74 were found due to arthrogryposis with prenatal death, either 
as intrauterine death or terminated pregnancy. Among this group, a 
distinct subset of 39 cases consisted of LCCS fetuses. During 1987-2002, 
the total number of recorded births was 984 743. Hence, the new 
incidence for LCCS was estimated at 1: 25 250 births (39 cases to 984743 
births) as opposed to the prior estimate of 1:19 000 births.  
Previously, 8% of affected newborns have suffered death within the first 
year of life in a Canadian series of 350 cases (Hall, 1985). In our study, the 
observed frequency of lethal arthrogryposis was markedly higher, 
presumably due to the enrichment of LCCS and LAAHD in the finnish 
gene pool. 
Transcript analysis (Publication II) 
To determine which genes and underlying molecular mechanisms are 
disturbed in LCCS, and thus essential for normal development of anterior 
motoneurons, we compared gene expression profiles of LCCS spinal cords 
against their respective age-matched controls. By the application of 
contemporary bioinformatics during data analysis, changes in pathways 
central in the development of the CNS were observed. Particularly, Olig2 
and Nkx2.2, two transcription factors crucial in the development of 
oligodendrocytes from the pMN domain, were observed to be 
downregulated in LCCS spinal cord. Further, several myelin related 
components were heavily downregulated fitting the hypothesis of an 
oligodendrocyte dysfunction shown in figure 8.  
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Data Analysis to identify deviating transcripts in LCCS spinal cord 
Global linear scaling was performed on the intensity values from the 
scanned images of the microarray chips. The normalizing of data for each 
individual gene to its median value across all probe arrays removed the 
occurrence of intensity-dependent bias in further analyses. After filtering 
out data of lesser quality and various data points pertaining to quality 
control probes, the initial 22 283 transcripts were reduced to 9 286. 
Within- and between group distribution of signal ratios, as well as their 
variance, were evaluated through analysis of log-log scatter plots of all 
possible pair-wise comparisons between probe arrays.  This information, 
giving us an estimate of the variability caused by biological and technical 
noise, was used to determine cut-off levels to discriminate significant 
changes from non-significant ones in expression profiles of LCCS samples 
and controls.  The cut-offs were applied individually to each sample-
control comparison, thus resulting in three sets of upregulated and three 
sets of downregulated genes. To further increase stringency, the finalized 
result lists contained only genes found to share the direction of regulation 
in all three comparisons. This conservative approach identified a total of 
34 genes as being significantly downregulated, the negative expression 
change between LCCS samples and controls ranging from two up to 15-
Figure 8. Hypothesized pathogenesis of myelin downregulation in LCCS where 
the downregulation of Olig2 and Nkx2.2 leads to an oligodendrocyte dysfunction  
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fold. Only three genes were found to be significantly upregulated, 
expression levels changing from two up to over 5-fold.   
Genetic networks 
The upregulated genes in the spinal cord samples of the LCCS fetuses 
consisted of only three transcripts: WIF1, MAB21L1 and ARL7.  Both 
WIF1 and MAB21L1 represent crucial genes for early fetal development 
and ARL7 is involved in cellular traffic. WIF1 is an inhibitor of Wnt 
signaling (Hsieh et al., 1999). Wnts are secreted molecules assigned to a 
vast amount of developmental processes, and they have been implicated  
in pre- and postsynaptic differentiation during Drosophila (Drosophila 
melanogaster) development (Packard et al., 2002). MAB21L is a homolog 
of the C. elegans (Caenorhabditis elegans) mab-21 cell fate specification 
gene (Mariani et al., 1999). Mab-21 has been implicated as a downstream 
target of TGFbeta (Morita et al., 1999). ARL7 represents a subgroup of 
the ARF family together with ARL4 and ARL6. The function of these 
genes is still unclear, and it has been speculated that they may be involved 
with protein transport between cell organelles (Jacobs et al., 1999).
ZHFX1B, which shows a significant downregulation of expression in 
LCCS spinal cords, can be linked to the same TGFbeta pathway as 
MAB21L. ZHFX1B is a zinc finger homeobox 1b transcription factor that 
binds SMAD and represses SMAD-mediated transcriptional activation 
(Verschueren et al., 1999).  SMAD transcription factors are mediators of 
the TGFbeta-family (Derynck and Zhang, 2003) and activation of SMAD 
is thought to lead to inhibition of MAB-21 (Morita et al., 1999). ZHFX1B 
is activated by Churchill, a zinc finger transcriptional activator that 
switches between different functions of Fibroblast Growth Factor (FGF) 
signaling (Sheng et al., 2003). ZHFX1B associates with SMAD1 only when 
the latter is phosphorylated, therefore acting as a putative sensor of Bone 
Morphogenetic Protein (BMP) activity in the cell (Postigo et al., 2003; 
55
Sheng et al., 2003). FGF signaling on the other hand has been shown to be 
involved in motoneuron development by controlling Hox expression 
(Dasen et al., 2003).  These data suggest links between different 
developmental pathways operating in the development of human spinal 
cord.
Spinal cord development 
Motoneurons develop from the pMN domain of the anterior spinal cord 
under the influence of a set of transcription factors. Especially SHH has 
been implicated as central in the process of determining the identity of the 
progenitor cells of the spinal cord. Mutations of SHH in human have been 
noted as causative of holoprosencephaly (Roessler et al., 1996) and also to 
impair neural patterning activity (Schell-Apacik et al., 2003). The intensity 
levels of SHH were below the detection limit on the genechips, and thus 
we were not able to deduce any changes in expression between the LCCS-
patients and controls. However, we could observe changes in the 
expression in factors linked to the SHH-signaling pathway, especially of a 
few involved in the specification of the pMN domain. In our experiments, 
the expression of PAX6 was marginally upregulated, and the expression of 
OLIG2 shows downregulation in the LCCS spinal cord. NKX2.2 also 
shows marginal downregulation of expression. PAX6 has been shown to 
repress the expression of NKX2.2 (Ericson et al., 1997; Jessell, 2000). 
From the phylogenetic footprinting and transcription factor analysis we 
identified PAX6 as a putative regulator of the downregulated genes. 
Furthermore, a member of the TGF?-signaling pathway, MAB21L1, and a 
factor capable of binding Smad, ZHFX1B, show altered expression in 
LCCS spinal cord. There is some evidence pointing towards a genetic 
interaction between mab-21 and mab-18, which is a PAX6 homolog, 
adding to the complexity of networks (Ericson et al., 1992). We could not 
see ISL1 expression in the microarray experiments, but at least  
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conventional RT-PCR reveals expression of ISL1 from LCCS spinal cords, 
thus making it possible that motoneurons are formed in LCCS-patients. 
We also looked at GLI-signaling to see if there were any significant 
changes in that signaling pathway, but we could only detect marginal 
upregulation of GLI2. By summarizing the findings above, we found 
alterations in several components in the pathways leading to mature 
motoneurons. These changes seem to be of a relatively high magnitude, 
since the cellular populations expressing such components define only a 
subset of the spinal cord and hence the signal may get diluted as we did 
not specifically dissect subregions of the spinal cord for this analysis.  
Identifying PAX6 as a regulatory transcription factor 
To identify common transcriptional motifs and transcription factors 
resulting in the observed expression patterns, phylogenetic footprinting 
methods were utilized. Amongst the set of 34 transcripts being 
downregulated in all LCCS patients, Paired-box gene 6 (PAX6) was found 
as a transcription factor with statistical significance in both tests compared 
to the control dataset and being overrepresented in the set of genes 
downregulated in LCCS. PAX6 plays an important role in central nervous 
system development and PAX6-null mice exhibit anopthalmia with central 
nervous system defects and lethality (Kioussi et al., 1999). PAX6 is 
conserved from invertebrates to vertebrates and functions as a regulator in 
central developmental processes of several organs (Chi and Epstein, 2002).  
Transcript analysis was also performed with one LAAHD spinal cord 
sample. The result was in line with the LCCS samples, indicating close 
similarities in the disease molecular pathways. However, detailed 
conclusions are not possible due to the analysis of only one sample. In 
addition, we looked at the transcript profiles of fetal diaphragmatic muscle 
from one LCCS patient as compared to an age-matched control. Severe 
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downregulation of myosin heavy chain expression could be observed as 
well as other findings. These data remain unpublish until additional 
samples are obtained for analysis. 
Neural precursor cells (Publication III) 
Since the global transcript analysis with LCCS fetuses suggested defects in 
the development of motoneurons and oligodendrocytes (Pakkasjarvi et al., 
2005), we addressed the question of differentiation experimentally. We 
isolated neural precursor cells from fetal 
central nervous system by growing 
homogenized biopsies in non-adherent 
conditions where they form neurospheres 
and can be cultured in the presence of 
mitogens (EGF, FGF and LIF) for 
extended passages. No macroscopic 
differences between LCCS- and control neurospheres could be observed 
when the cells were maintained undifferentiated and both cell lines were 
passaged for extended periods (>P20). However, the LCCS neurospheres 
appeared to grow slightly denser as compared to the controls. To study the 
proportion of dividing cells in culture, neural precursor cells were 
subjected to BrdU to stain for mitotic cells. On average, 7% of LCCS 
NPCs stained positive for BrdU-incorporation, whereas only 3% of 
control NPCs were positive, indicating an increase in proliferation in 
LCCS NPCs. A neurosphere stained with anti-BrdU to detect mitotic cells 
is shown in figure 9, where the amount of dividing cells can be visually 
observed.  
To determine the molecular background of the observed increase in 
mitotic activity, the expression profiles of LCCS undifferentiated neural 
Figure 9. BrdU positive 
cells (red) in neurosphere 
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precursor cells were compared to their respective controls. This 
conservative approach identified a total of 49 genes as being significantly 
upregulated, the expression change between LCCS samples and controls 
ranging from two up to 27-fold. 63 genes were found to be significantly 
downregulated, the negative expression levels changing from two up to 
over 15-fold. The lists of significantly up-/down-regulated genes were 
examined for biologically relevant associations using the Web-based Gene Set 
Analysis Toolkit available at http://genereg.ornl.gov/webgestalt/.
Annotation information defining the biological processes to which each 
gene could be ascribed to was retrieved from the classifications provided 
by the gene ontology (GO) consortium (Ashburner et al., 2000), the  Kyoto
Encyclopedia of Genes and Genomes (KEGG) and BioCarta. Statistical 
evaluation of enrichment of categories represented in each gene list, 
compared to the proportion observed in the total population of genes on 
the probe array, was performed using the hypergeometric test and p-values 
less than 0.01 were considered significant.
This analysis indicated the Epidermal Growth Factor Receptor processing 
as being enriched in the upregulated undifferentiated NPC samples. The 
EGFR is a tyrosine kinase and signaling involves small GTPases of the 
Rho family (Wong and Guillaud, 2004). The oncogene ERBB is implicated 
to derive from EGFR and mutations in EGFR have been associated with 
small-cell lung cancer (Downward et al., 1984; Kobayashi et al., 1995). 
EGF is essential to the maintenance of neural precursor cells and EGFR 
levels are known to determine progenitor cell proliferation and 
differentiation (Lillien, 1995). These findings support the observed 
proliferative activity of LCCS NPCs. However, further experiments are 
warranted before definitive conclusions, as the biology of NPCs in 
neurosphereculture is still not completely understood. The in vitro setting 
for the creation of the appropriate niche remain precarious despite recent 
progress in the field (Shen et al., 2004). It is known that more than one 
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kind of precursor cells are present in the nervous system and that the 
different precursor cells exist at different times during development (Rao, 
2004), which may limit our study with the human samples. Further, not 
only true precursor cells display self-renewal capacity (Trentin et al., 2004). 
Still, the transcriptome analysis revealed the molecules associated with 
proliferative activity and supports the notion that EGF-responsive cells are 
present at later stages of development (Svendsen et al., 1996). Indeed, a 
derangement of developmental timing may be critical for the survival of 
motoneurons (Hausmanowa-Petrusewicz and Vrbova, 2005) and the 
observed proliferation change may cause developmental delays that render 
the LCCS motoneurons vulnerable at later stages. 
To determine the potential to differentiate, the neural precursor cells were 
analysed during withdrawal of mitogens. Both LCCS and control derived 
neural precursor cells differentiated into neurons and cells of glial lineage. 
We stained cells for neuronal (neuronal class III ?-tubulin), astrocyte 
(GFAP) and motoneuron (Islet-1, Hb9) markers as the cells were 
challenged by fetal calf serum addition after mitogen withdrawal.  No 
macroscopic differences were observed between LCCS patients and 
controls in the number or appearance of the differentiated cells. Wu et al. 
have previously shown that by priming NPCs, many will aquire a 
cholinergic phenotype upon grafting into spinal cord (Wu et al., 2002). 
Gao et al. also showed how this approach was succesfully used for 
innervation of peripheral muscle with primed NPCs in rats suffering from 
motoneuron degeneration (Gao et al., 2005). In our hands, priming of 
neural precursor cells in vitro did not increase the percentages of cells 
positive for motoneuron markers. To address the question of 
oligodendrocyte development, the precursor cells were supplied with IGF-
1 and stained after differentiation for the oligodendrocyte marker O4. 
Again, no differences between patients and controls could be observed.  
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Figure 10 shows oligodendrocyte marker positive cells from differentiated 
LCCS NPCs. To further study the differentiation of NPCs into 
motoneurons, the cells were stained with choline acetyltransferase (Chat), 
a marker found in mature cholinergic motoneurons. We could not identify 
truly Chat-positive cells in our cultures. It is possible that our culture 
conditions do not favor the final maturation of motoneurons into 
cholinergic cells in the absence of further environmental clues. However, 
we are confident that our experiments show clear induction of 
differentiation and immunocytochemical evidence of cell fates that are 
affected in LCCS. 
To investigate whether excessive apoptosis occurs during the 
differentiation of LCCS derived neurospheres, we differentiated both 
LCCS and control neurospheres and measured apoptosis by fluorescence-
activated cell sorting. Apoptosis was studied by detecting the translocation 
of phosphatidylserine to the extracellular side of the cytoplasmic 
membrane, an early indicator of apoptosis (Vermes et al., 1995). Necrotic 
cells were detected by DNA staining with propidium iodide to distinguish 
apoptotic and necrotic cells. Of the LCCS patients, 25% (n=5, SD=6.3) of 
the differentiated cells were apoptotic, whereas the number for controls 
was 17% (n=3, SD=6.8). Although the mean number of apoptotic cells 
was higher in LCCS derived progenitors, statistically significant differences 
could not be detected (student t-test p-value 0,29). The proportion of 
Figure 10. Oligodendrocyte O4-
marker positive cells 
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necrotic cells was also similar in LCCS and control cultures (19%, SD=5.2  
and 18%, SD=4.6, student t-test p-value 0,53).  An exaggeration of 
naturally occuring PCD of motoneurons has been proposed as a part of 
the pathogenesis of spinal muscular atrophy (Fidzianska and Rafalowska, 
2002; Soler-Botija et al., 2002). The pathogenesis behind the lack of 
anterior horn tissue in LCCS has remained unknown and speculations on 
an inability to produce the appropriate cell types or whether excessive 
PCD eliminates cells after differentiation have occured. We compared 
PCD during initial differentiation of NPCs, but statistically significant 
differences in PCD could not be observed. To further address the 
question of motoneuronal cell death, we would have to enrich for 
motoneurons and then pursue the apoptosis assays. 
To address any molecular disturbances during differentiation of neural 
precursor cells, RNA was collected from neurospheres and differentiated 
precursor cells from both LCCS-patients and the controls. The RNA was 
utilized in transcriptome analyses with commercial microarray chips. 
Aberrant gene expression in LCCS patients could be detected. Combining 
the gene lists of abberantly expressed transcripts in both  neurospheres 
and differentiated cells yielded a set of 8 genes putatively active during 
initiation of the disease process. The transcripts that were upregulated in 
both conditions consisted of: (1) RBPMS, coding for an RNA binding 
protein; (2) URB, a steroid sensitive gene (Aoki et al., 2002); (3) 
GLT25D2, a gene containing a glycosyltransferase domain; (4) 
XM_371647, a transcript with a putative glycosyltransferase domain; (5) 
PIPOX, a gene with oxidase activity (Dodt et al., 2000). The 
downregulated transcipts common to both conditions consisted of: (1) 
PHACTR2 and (2) PHACTR3, two genes with phosphatase and actin 
regulator activity (Allen et al., 2004); and (3) PAK7, a brain specific gene 
encoding for a protein with serine/threonine kinase activity (Waterston et 
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al., 2002).  Another member of the PAK-family was also observed to be 
downregulated in the undifferentiated NPCs, namely PAK3. In addition, 
EDG4, a lysophosphatidic acid G-protein-coupled receptor was observed 
to be downregulated. Lysophosphatidic acid has been recognized as an 
activator of the Rho family of GTPases, which use PAK7 as a downstream 
effector.
In this study, we isolated and cultured NPCs from fetal LCCS brains. We 
demonstrate that despite the genetic defect leading to the absence of 
motoneurons in the patients, the NPCs retain the potential to differentiate 
into distinct cell types of the CNS. We also provide evidence that after 
differentiation the cells do not undergo excessive apoptosis. The gene 
expression changes support and explain the observation of an increased 
growth rate  of NPCs. Thus, the disease may be due to a non-cell 
autonomous mechanism at the stem cell level meaning defective niche 
circumstances. It may as well be due to defects in interaction of cells at 
later stages.  
We also isolated neural precursor cells from the spinal cord of one LCCS 
fetus successfully. The growth kinetics of spinal cord derived NPCs are 
however too slow for further analysis with current in vitro niche 
conditions and thus, any true conclusions cannot be drawn based on these 
experiments. It is possible that the pool of spinal cord precursor cells is 
small and the culture conditions are not optimal for the necessary 
propagation of these cells to enable similar studies as was done for the 
brain NPCs. 
Of interest to note is, that priorly it has been unclear whether cells of 
spinal cord origin can be generated from brain derived neural precursor 
cells and only a small number of publications providing definitive evidence 
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are currently found (Wu et al., 2002; Gao et al., 2005). We show that cells 
expressing motoneuron markers can be differentiated from the human 
neural precursor cells in vitro. Their functional capacity awaits analysis. 
These CNS NPCs do not represent a developmentally relevant pool of 
motoneuron precursors, however, the results obtained provide further 
evidence to previous studies with CNS NPCs and motoneurons.
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Synopsis 
The incidence of anterior horn cell disorders associated with 
arthrogryposis and early fetal demise is poorly known. Although obviously 
rare, early onset lethal arthrogryposes constitute a significant problem to 
the affected families due to the risk of recurrence. They are a diagnostic 
challenge to obstetricians performing ultrasonographic investigations as 
well as to geneticists giving genetic counseling. Thus, more knowledge 
about the genetics and epidemiology of these disorders are needed. 
Importantly, identification of the defective pathways in these disorders 
would most probably expose critical elements in the normal development 
of human motoneurons. 
This thesis describes the localization of the LCCS disease gene to 
chromosome 9q34.1 by linkage mapping. Despite high hopes and intense 
investigations, the true molecular background of LCCS remains unknown. 
The physical mapping of the region advanced paralleled to the progress of 
the Human Genome Project and provided at later stages novel 
information to the sequencing effort. Candidate genes were localized to 
the region, several of which had not previously been assigned to a specific 
genomic region. Sequencing of these genes witnessed the evolution of 
Sangers dideoxy chain termination reactions by manual propagation to the 
era of automated sequencers. However, none of the obvious candidate 
genes contained disease causing mutations, neither did their expression 
levels indicate any association to LCCS. To try an alternative approach, 
microRNA genes were predicted from the critical 9q34.1 region, but none 
of the identified microRNAgenes were mutated in LCCS. It may well be 
that the mutation lies in a regulatory element in 9q34.1, but the gene 
regulated is further away from this region. Therefore, interesting times are 
ahead once the gene defect is verified.  
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As another alternative avenue to identify involved genes and pathways and 
to gain further insight into the molecular pathways that are disturbed 
during the pathogenesis of LCCS, a global trancript analysis was 
performed. RNA from fresh LCCS spinal cord and age matched controls 
was isolated and analyzed with commercial microarray methods. An 
indicative oligodendrocyte dysfunction was recognized with specific 
changes in the expression of distinct transcription factors central in the 
development of the spinal cord. In detail, Olig2 and Nkx2.2 showed 
downregulation in expression in LCCS; two transcription factors of 
importance during both motoneuron and oligodendrocyte development. 
Further, downregulation in components of the oligodendrocyte product 
myelin were observed. The microarray study provided a still shot of a 
distinct phase in the pathogenesis of LCCS and many questions evolved.  
To analyze the differentiation of neurons and cells of glial origin during 
the LCCS pathogenesis further, neural precursor cells were harvested from 
post-mortem LCCS CNS. In vitro studies showed an increase in the 
proliferative activity of LCCS NPCs and the neurospheres also grew 
denser as compared to the controls. When differentiated, no 
morphological differences between patients and controls could be 
observed, and both lines readily differentiated into neurons, astrocytes, 
motoneuron-like cells and oligodendrocytes upon instruction. However, 
molecular changes could already be observed in microarray analyses from 
differentiating NPC cells. The true impact of these changes claim 
extensive further studies, but provide a glimpse into the molecular details 
of progenitor cell differentiation.  
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6. CONCLUDING REMARKS 
More than 150 conditions presenting with arthrogryposis multiplex 
congenita are known (Hall, 1985; Hall, 2002). Most of these conditions, 
however, can accurately be diagnosed only after birth and in living 
patients. Prenatally lethal cases of arthrogryposis still remain a challenge 
although they are more and more frequently encountered due to improved 
ultrasound methods.  Post-mortem diagnostics is often hampered by fetal 
maseration  as a function of intrauterine retention time. Therefore, 
accurate diagnosis is at times only descriptive and prognosis is not always 
possible to predict. When lethal arthrogryposis is suspected in ultrasound 
due to immobility, a regular and intense follow-up is recommended.  
The estimated birth prevalence of arthrogryposis varies greatly depending 
on the definition of the condition and the type of study. Multiple 
congenital contractures (arthrogryposis) has been estimated to occur with 
a frequency of about 1:3000 live births and about 1 in every 200 newborns 
is estimated to be born with some form of contractures (Hall, 1997; Hall, 
2002). In this study, we estimated the birth prevalence of LCCS to 1: 
25300 births through a register based study. The epidemiology of early 
onset lethal arthrogryposis is poorly known, but unpublished results 
indicate a relatively high frequency of the perinatally lethal cases which 
usually have been omitted in previous studies. This puts emphasis on the 
burden caused by these entities for the parents. Clearly more studies of the 
very early onset and prenatally diagnosed cases are needed to enable 
proper genetic counseling and prenatal diagnosis. 
This thesis work has used of different approaches towards the 
understanding of disease mechanisms. The first publication  shows how 
linkage studies have been carried out using only a few individuals. 
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Previously unpublished results present the inherent difficulties in 
identifiying disease affecting mutations. The second publication utilizes 
global transcript analysis and contemporary bioinformatics in deciphering 
clues to the molecular pathways deranged during the disease process. In 
the third publication human neural precursor cells have been utilized in 
disease mechanisms. It provides an innovative approach to study a 
developmental neurologic disease and shows that cells expressing 
motoneuron markers can be generated directly from neural precursor cells 
in vitro. 
The intricate developmental network is subjective to disturbances at 
multiple occasions. This thesis shows that most of the developmental 
checkpoints of the spinal cord are passed normally at least in culture in 
LCCS patients. Most probably, the disease mechanism is active at post-
mitotic stages of the spinal cord cells. The revelation of the genetic defect 
ensures interesting times ahead. 
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